Journal of Ophthalmology
Volume 2014 (2014), Article ID 128903, 5 pages
http://dx.doi.org/10.1155/2014/128903
Clinical Study
Methotrexate for the Treatment of Thyroid Eye Disease
1Department of Neuroscience, Odontostomatological and Reproductive Sciences, University “Federico II” of Naples, Via Pansini No. 5, 80131 Naples, Italy
2Department of Endocrinology, Second University of Naples, Italy
Received 12 August 2013; Revised 30 October 2013; Accepted 2 November 2013; Published 8 January 2014
Academic Editor: Torben Lykke Sørensen
Copyright © 2014 Diego Strianese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- R. S. Bahn, “Graves' ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 726–774, 2010. View at Publisher · View at Google Scholar · View at Scopus
- M. Comerci, A. Elefante, D. Strianese et al., “Semiautomatic regional segmentation to measure orbital fat volumes in thyroid-associated ophthalmopathy. Avalidation study,” The Neuroradiology Journal, vol. 26, no. 4, pp. 373–379, 2013. View at Google Scholar
- G. Uccello, P. Vassallo, D. Strianese, and G. Bonavolonta, “Free levator complex recession in Graves' ophthalmopathy. Our experience,” Orbit, vol. 13, no. 3, pp. 119–123, 1994. View at Google Scholar · View at Scopus
- H. Koshiyama, T. Koh, K. Fujiwara, K. Hayakawa, S.-I. Shimbo, and T. Misaki, “Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation,” Thyroid, vol. 4, no. 4, pp. 409–413, 1994. View at Google Scholar · View at Scopus
- W. M. Wiersinga and M. F. Prummel, “Graves' ophthalmopathy: a rational approach to treatment,” Trends in Endocrinology and Metabolism, vol. 13, no. 7, pp. 280–287, 2002. View at Publisher · View at Google Scholar · View at Scopus
- L. Bartalena, C. Marcocci, M. Tanda, and A. Pinchera, “Management of thyroid eye disease,” European Journal of Nuclear Medicine, vol. 29, no. 2, pp. S458–S465, 2002. View at Google Scholar · View at Scopus
- G. E. Krassas and A. E. Heufelder, “Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts,” European Journal of Endocrinology, vol. 144, no. 4, pp. 311–318, 2001. View at Google Scholar · View at Scopus
- C. Marcocci, G. J. Kahaly, G. E. Krassas et al., “Selenium and the course of mild Graves' orbitopathy,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1920–1931, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. P. Mourits, M. L. Van Kempen-Harteveld, M. B. García García, H. P. F. Koppeschaar, L. Tick, and C. B. Terwee, “Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study,” The Lancet, vol. 355, no. 9214, pp. 1505–1509, 2000. View at Google Scholar · View at Scopus
- N. Minakarau and D. G. Ezra, “Rituximab for thyroid-associated ophthalmopathy,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD009226, 2013. View at Google Scholar
- P. Sanyal, R. G. Bing-You, and L. E. Braverman, “Use of methotrexate to treat isolated graves ophthalmopathy developing years after thyroidectomy and iodine 131 treatment of papillary thyroid cancer,” Endocrine Practice, vol. 14, no. 4, pp. 422–425, 2008. View at Google Scholar · View at Scopus
- L. Bartalena, C. Marcocci, M. L. Tanda et al., “Orbital radiotherapy for Graves' ophthalmopathy,” Thyroid, vol. 12, no. 3, pp. 245–250, 2002. View at Google Scholar · View at Scopus
- M. F. Prummel, A. Berghout, W. M. Wiersinga, M. P. Mourits, L. Koornneef, and L. Blank, “Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy,” The Lancet, vol. 342, no. 8877, pp. 949–954, 1993. View at Publisher · View at Google Scholar · View at Scopus
- J. R. Smith and J. T. Rosenbaum, “A role for methotrexate in the management of non-infectious orbital inflammatory disease,” British Journal of Ophthalmology, vol. 85, no. 10, pp. 1220–1224, 2001. View at Publisher · View at Google Scholar · View at Scopus
- L. Bartalena, M. L. Tanda, A. Medea et al., “Novel approaches to the management of Graves' ophtalmopathy,” Hormones, vol. 1, no. 2, pp. 76–90, 2002. View at Google Scholar
- D. Strianese, R. Piscopo, and A. Elefante, “Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study,” BMC Ophthalmology, vol. 13, p. 21, 2013. View at Google Scholar
- M. P. Mourits, M. F. Prummel, W. M. Wiersinga, and L. Koornneef, “Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy,” Clinical Endocrinology, vol. 47, no. 1, pp. 9–14, 1997. View at Google Scholar · View at Scopus
- A. Pinchera, W. Wiersinga, D. Glinoer et al., “Classification of eye changes of Graves' disease,” Thyroid, vol. 2, no. 3, pp. 235–236, 1992. View at Google Scholar
- P. J. Dolman, K. Cahill, C. N. Czyz et al., “Reliability of estimating ductions in thyroid eye disease: an international thyroid eye disease society multicenter study,” Ophthalmology, vol. 119, no. 2, pp. 382–389, 2012. View at Publisher · View at Google Scholar · View at Scopus
- F. F. Rundie, “Development and course of exophthalmos and ophthalmoplegia in Graves' diseasee with special reference to the effect of thyroidectomy,” Clinical Science, vol. 5, pp. 177–194, 1945. View at Google Scholar
- N. Songsiridej and D. E. Furst, “Methotrexate—the rapidly acting drug,” Bailliere's Clinical Rheumatology, vol. 4, no. 3, pp. 575–593, 1990. View at Google Scholar · View at Scopus
- R. Le Moli, L. Baldeschi, P. Saeed, N. Regensburg, M. P. Mourits, and W. M. Wiersinga, “Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy,” Thyroid, vol. 17, no. 4, pp. 357–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
- M. Seitz, “Molecular and cellular effects of methotrexate,” Current Opinion in Rheumatology, vol. 11, no. 3, pp. 226–232, 1999. View at Publisher · View at Google Scholar · View at Scopus
- D. S. Rampton, “Methotrexate in Crohn's disease,” Gut, vol. 48, no. 6, pp. 790–791, 2001. View at Publisher · View at Google Scholar · View at Scopus
- L. Bartalena, A. Pinchera, and C. Marcocci, “Management of graves' ophthalmopathy: reality and perspectives,” Endocrine Reviews, vol. 21, no. 2, pp. 168–199, 2000. View at Publisher · View at Google Scholar · View at Scopus
- G. S. Alarcón, J. M. Kremer, M. Macaluso et al., “Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study,” Annals of Internal Medicine, vol. 127, no. 5, pp. 356–364, 1997. View at Google Scholar · View at Scopus
- N. D'Andrea, L. Triolo, G. Margagnoni, A. Aratari, and C. M. Sanguinetti, “Methotrexate-induced pneumonitis in Crohn's disease: case report and review of the literature,” Multidisciplinary Respiratory Medicine, vol. 5, no. 5, pp. 312–319, 2010. View at Google Scholar · View at Scopus
- H. Amital, Y. Arnson, G. Chodick, and V. Shalev, “Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate,” Rheumatology, vol. 48, no. 9, pp. 1107–1110, 2009. View at Publisher · View at Google Scholar · View at Scopus
- F. Menconi, M. A. Profilo, M. Leo et al., “Spontaneous improvement of untreated mild Graves' ophthalmopathy: the Rundle curve revisited,” Thyroid, 2013. View at Google Scholar
- L. Baldeschi, K. Macandie, E. Koetsier, L. E. C. M. Blank, and W. M. Wiersinga, “The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in graves orbitopathy,” American Journal of Ophthalmology, vol. 145, no. 3, pp. 534–540, 2008. View at Publisher · View at Google Scholar · View at Scopus